collection
MENU ▼
Read by QxMD icon Read
search

Mama

shared collection
58 papers 25 to 100 followers
By Alessandro Franciscon doctor
https://www.readbyqxmd.com/read/30145393/hypofractionated-whole-breast-irradiation-in-large-breasted-women-is-there-a-dosimetric-predictor-for-acute-skin-toxicities
#1
Ankur K Patel, Diane C Ling, Adam H Richman, Colin E Champ, M Saiful Huq, Dwight E Heron, Sushil Beriwal
PURPOSE: Underutilization of hypofractionated whole breast irradiation (HF-WBI) in large-breasted women may be partially explained by concerns about dose heterogeneity. While modern planning may mitigate this issue, validated dosimetric guidelines are lacking. Our clinical pathway mandates hypofractionation, guided by institutional dosimetric criteria for plan evaluation. We examined acute radiation dermatitis rates with HF-WBI in large-breasted patients when our guidelines are followed and evaluated factors predictive for dermatitis...
August 23, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28954300/impact-of-radiotherapy-on-complications-and-patient-reported-outcomes-after-breast-reconstruction
#2
MULTICENTER STUDY
Reshma Jagsi, Adeyiza O Momoh, Ji Qi, Jennifer B Hamill, Jessica Billig, Hyungjin M Kim, Andrea L Pusic, Edwin G Wilkins
Background: Patients considering postmastectomy radiation and reconstruction require information regarding expected outcomes to make preference-concordant decisions. Methods: A prospective multicenter cohort study of women diagnosed with breast cancer at 11 centers between 2012 and 2015 compared complications and patient-reported outcomes of 622 irradiated and 1625 unirradiated patients who received reconstruction. Patient characteristics and outcomes between irradiated and unirradiated patients were analyzed using ttests for continuous variables and chi-square tests for categorical variables...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28358936/association-of-radiotherapy-boost-for-ductal-carcinoma-in-situ-with-local-control-after-whole-breast-radiotherapy
#3
MULTICENTER STUDY
Meena S Moran, Yinjun Zhao, Shuangge Ma, Youlia Kirova, Alain Fourquet, Peter Chen, Karen Hoffman, Kelly Hunt, Julia Wong, Lia M Halasz, Gary Freedman, Robert Prosnitz, Michael Yassa, David H A Nguyen, Tarek Hijal, Bruce G Haffty, Elaine S Wai, Pauline T Truong
Importance: The use of a radiotherapy (RT) boost to the tumor bed after whole-breast RT (WBRT) for ductal carcinoma in situ (DCIS) is largely extrapolated from invasive cancer data, but robust evidence specific to DCIS is lacking. Objective: To compare ipsilateral breast tumor recurrence (IBTR) in women with DCIS treated with vs without the RT boost after breast-conserving surgery and WBRT. Design, Setting, and Participants: This retrospective analysis pooled deidentified patient-level data from 10 academic institutions in the United States, Canada, and France from January 1, 1980, through December 31, 2010...
August 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28459606/hypofractionated-postmastectomy-radiation-therapy-is-safe-and-effective-first-results-from-a-prospective-phase-ii-trial
#4
Atif J Khan, Matthew M Poppe, Sharad Goyal, Kristine E Kokeny, Thomas Kearney, Laurie Kirstein, Deborah Toppmeyer, Dirk F Moore, Chunxia Chen, David K Gaffney, Bruce G Haffty
Purpose Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 weeks. Data supporting hypofractionated PMRT is limited. We prospectively evaluated a short course of hypofractionated PMRT, in which therapy was completed in 15 treatment days. Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days to the chest wall and the draining regional lymph nodes, followed by an optional mastectomy scar boost of four fractions of 3.33 Gy...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/16198508/a-phase-i-ii-trial-to-evaluate-three-dimensional-conformal-radiation-therapy-confined-to-the-region-of-the-lumpectomy-cavity-for-stage-i-ii-breast-carcinoma-initial-report-of-feasibility-and-reproducibility-of-radiation-therapy-oncology-group-rtog-study-0319
#5
MULTICENTER STUDY
Frank Vicini, Kathryn Winter, William Straube, John Wong, Helen Pass, Rachel Rabinovitch, Susan Chafe, Douglas Arthur, Ivy Petersen, Beryl McCormick
BACKGROUND: This prospective study (Radiation Therapy Oncology Group Study 0319) examines the use of three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Reproducibility, as measured by technical feasibility, was the primary end point with the goal of demonstrating whether the technique is widely applicable in a multicenter setting before a Phase III trial is undertaken. METHODS AND MATERIALS: This study was designed such that if fewer than 5 cases out of the first 42 patients evaluable were scored as unacceptable, the treatment would be considered reproducible...
December 1, 2005: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28779963/partial-breast-radiotherapy-after-breast-conservation-surgery-for-patients-with-early-breast-cancer-uk-import-low-trial-5-year-results-from-a-multicentre-randomised-controlled-phase-3-non-inferiority-trial
#6
RANDOMIZED CONTROLLED TRIAL
Charlotte E Coles, Clare L Griffin, Anna M Kirby, Jenny Titley, Rajiv K Agrawal, Abdulla Alhasso, Indrani S Bhattacharya, Adrian M Brunt, Laura Ciurlionis, Charlie Chan, Ellen M Donovan, Marie A Emson, Adrian N Harnett, Joanne S Haviland, Penelope Hopwood, Monica L Jefford, Ronald Kaggwa, Elinor J Sawyer, Isabel Syndikus, Yat M Tsang, Duncan A Wheatley, Maggie Wilcox, John R Yarnold, Judith M Bliss
BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy. METHODS: IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK...
September 9, 2017: Lancet
https://www.readbyqxmd.com/read/29208440/radiotherapy-in-the-setting-of-breast-reconstruction-types-techniques-and-timing
#7
REVIEW
Alice Y Ho, Zishuo I Hu, Babak J Mehrara, Edwin G Wilkins
As the use of breast reconstruction and postmastectomy radiotherapy (PMRT) has increased over the past decade, the typical approach to integrating radiotherapy with breast reconstruction has provoked intense controversy in the management of breast cancer. PMRT can lead to an increased frequency of complications in the reconstructed breast. Conversely, the reconstructed breast can increase the complexity of radiotherapy delivery. How to minimise the frequency of complications without compromising oncological or cosmetic outcomes of the reconstructed breast is an important shared multidisciplinary goal for oncologists and their patients...
December 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29254776/breast-cancer-biology-clinical-implications-for-breast-radiation-therapy
#8
REVIEW
Janet K Horton, Reshma Jagsi, Wendy A Woodward, Alice Ho
Historically, prognosis and treatment decision making for breast cancer patients have been dictated by the anatomic extent of tumor spread. However, in recent years, "breast cancer" has proven to be a collection of unique phenotypes with distinct prognoses, patterns of failure, and treatment responses. Recent advances in biologically based assays and targeted therapies designed to exploit these unique phenotypes have profoundly altered systemic therapy practice patterns and treatment outcomes. Data associating locoregional outcomes with tumor biology are emerging...
January 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29165285/hypofractionated-nodal-radiation-therapy-for-breast-cancer-was-not-associated-with-increased-patient-reported-arm-or-brachial-plexopathy-symptoms
#9
MULTICENTER STUDY
Nelson Leong, Pauline T Truong, Keith Tankel, Winkle Kwan, Lorna Weir, Ivo A Olivotto
PURPOSE: To determine whether nodal radiation therapy (RT) for breast cancer using modest hypofractionation (HF) with 2.25 to 2.5 Gy per fraction (fx) was associated with increased patient-reported arm symptoms, compared with conventional fractionation (CF) ≤2 Gy/fx. METHODS AND MATERIALS: Two cancer registries were used to identify subjects who received computed tomography-planned nodal RT for pT1-3, pN0-2, M0 breast cancer, from 2007 to 2010 at 2 cancer institutions...
December 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29153463/late-normal-tissue-effects-in-the-arm-and-shoulder-following-lymphatic-radiotherapy-results-from-the-uk-start-standardisation-of-breast-radiotherapy-trials
#10
RANDOMIZED CONTROLLED TRIAL
Joanne S Haviland, Mariella Mannino, Clare Griffin, Nuria Porta, Mark Sydenham, Judith M Bliss, John R Yarnold
BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with similarly-hypofractionated breast/chest wall radiotherapy (RT). MATERIAL AND METHODS: The Standardisation of Breast Radiotherapy (START) pilot, A and B trials randomised women with early breast cancer to schedules of 2.67-3.3 Gy versus 2.0 Gy fractions (control)...
January 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28898379/effect-of-axillary-dissection-vs-no-axillary-dissection-on-10-year-overall-survival-among-women-with-invasive-breast-cancer-and-sentinel-node-metastasis-the-acosog-z0011-alliance-randomized-clinical-trial
#11
RANDOMIZED CONTROLLED TRIAL
Armando E Giuliano, Karla V Ballman, Linda McCall, Peter D Beitsch, Meghan B Brennan, Pond R Kelemen, David W Ollila, Nora M Hansen, Pat W Whitworth, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow
Importance: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection...
September 12, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28943046/radical-radiation-therapy-for-oligometastatic-breast-cancer-results-of-a-prospective-phase-ii-trial
#12
Marco Trovo, Carlo Furlan, Jerry Polesel, Francesco Fiorica, Stefano Arcangeli, Niccolò Giaj-Levra, Filippo Alongi, Alessandro Del Conte, Loredana Militello, Elena Muraro, Debora Martorelli, Simon Spazzapan, Massimiliano Berretta
BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled...
January 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28822332/eso-esmo-3rd-international-consensus-guidelines-for-breast-cancer-in-young-women-bcy3
#13
Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, Omalkhair Abulkhair, Maria-João Cardoso, Rebecca Alexandra Dent, Karen Gelmon, Oreste Gentilini, Nadia Harbeck, Anita Margulies, Dror Meirow, Giancarlo Pruneri, Elzbieta Senkus, Tanja Spanic, Medha Sutliff, Luzia Travado, Fedro Peccatori, Fatima Cardoso
The 3rd International Consensus Conference for Breast Cancer in Young Women (BCY3) took place in November 2016, in Lugano, Switzerland organized by the European School of Oncology (ESO) and the European Society of Medical Oncologists (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY2 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA)...
October 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28391871/tamoxifen-with-radiotherapy-compared-with-tamoxifen-alone-in-elderly-women-with-early-stage-breast-cancer-treated-with-breast-conserving-surgery-a-systematic-review-and-meta-analysis
#14
REVIEW
Tyler R Chesney, Jennifer Xin Yin, Nikoo Rajaee, Andrea C Tricco, Anthony W Fyles, Sergio A Acuna, Adena S Scheer
BACKGROUND: Our aim was to assess the effect of adjuvant radiotherapy on recurrence and survival for elderly women (≥70) with early-stage hormone receptor-positive breast cancer treated with breast conserving surgery (BCS) and Tamoxifen. MATERIALS AND METHODS: MEDLINE, EMBASE, and Evidence-Based Medicine Reviews were systematically searched through August 12, 2016 for randomized controlled trials (RCTs) comparing radiotherapy to no radiotherapy and presenting outcomes for women ≥70years...
April 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28382401/management-of-the-positive-axilla-in-2017
#15
EDITORIAL
Eli Avisar, Tolga Ozmen
No abstract text is available yet for this article.
June 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/23032615/predictors-of-locoregional-recurrence-after-neoadjuvant-chemotherapy-results-from-combined-analysis-of-national-surgical-adjuvant-breast-and-bowel-project-b-18-and-b-27
#16
Eleftherios P Mamounas, Stewart J Anderson, James J Dignam, Harry D Bear, Thomas B Julian, Charles E Geyer, Alphonse Taghian, D Lawrence Wickerham, Norman Wolmark
PURPOSE: The limited information on predictors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph node biopsy. PATIENTS AND METHODS: We examined patterns and predictors of LRR as first event in combined analysis of two National Surgical Adjuvant Breast and Bowel Project (NSABP) neoadjuvant trials. NC was either doxorubicin/cyclophosphamide (AC) alone or AC followed by neoadjuvant/adjuvant docetaxel...
November 10, 2012: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/11773149/predictors-of-local-regional-recurrence-after-neoadjuvant-chemotherapy-and-mastectomy-without-radiation
#17
Thomas A Buchholz, Susan L Tucker, Lawrence Masullo, Henry M Kuerer, Jessica Erwin, Jessica Salas, Debbie Frye, Eric A Strom, Marsha D McNeese, George Perkins, Angela Katz, S Eva Singletary, Kelly K Hunt, Aman U Buzdar, Gabriel N Hortobagyi
PURPOSE: To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation. PATIENTS AND METHODS: We analyzed the outcome of the 150 breast cancer cases treated on prospective institutional trials with neoadjuvant chemotherapy and mastectomy without postmastectomy radiation. Clinical stage at diagnosis was I in 1%, II in 43%, IIIA in 23%, IIIB in 25%, and IV in 7%. No patient had inflammatory breast cancer...
January 1, 2002: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/10924981/is-radiation-alone-adequate-treatment-to-the-axilla-for-patients-with-limited-axillary-surgery-implications-for-treatment-after-a-positive-sentinel-node-biopsy
#18
S Galper, A Recht, B Silver, M V Bernardo, R Gelman, J Wong, S J Schnitt, J L Connolly, J R Harris
PURPOSE: To estimate the possible efficacy of axillary radiation therapy (AXRT) following a positive sentinel node biopsy (SNB), we evaluated the risk of regional nodal failure (RNF) for patients with clinical Stage I or II, clinically node-negative invasive breast cancer treated with either no dissection or a limited dissection (LD) defined as removal of 5 nodes or less followed by AXRT. MATERIALS AND METHODS: From 1978 to 1987, 292 patients underwent AXRT in the absence of axillary dissection; 126 underwent AXRT following LD...
August 1, 2000: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/23690420/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or-older-with-early-breast-cancer-long-term-follow-up-of-calgb-9343
#19
RANDOMIZED CONTROLLED TRIAL
Kevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, Constance T Cirrincione, Donald A Berry, Beryl McCormick, Hyman B Muss, Barbara L Smith, Clifford A Hudis, Eric P Winer, William C Wood
PURPOSE: To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. PATIENTS AND METHODS: Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women)...
July 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21900114/age-breast-cancer-subtype-approximation-and-local-recurrence-after-breast-conserving-therapy
#20
Nils D Arvold, Alphonse G Taghian, Andrzej Niemierko, Rita F Abi Raad, Meera Sreedhara, Paul L Nguyen, Jennifer R Bellon, Julia S Wong, Barbara L Smith, Jay R Harris
PURPOSE: Prior results of breast-conserving therapy (BCT) have shown substantial rates of local recurrence (LR) in young patients with breast cancer (BC). PATIENTS AND METHODS: We studied 1,434 consecutive patients with invasive BC who received BCT from December 1997 to July 2006. Ninety-one percent received adjuvant systemic therapy; no patients received trastuzumab. Five BC subtypes were approximated: estrogen receptor (ER) or progesterone receptor (PR) positive, HER2 negative, and grades 1 to 2 (ie, luminal A); ER positive or PR positive, HER2 negative, and grade 3 (ie, luminal B); ER or PR positive, and HER2 positive (ie, luminal HER2); ER negative, PR negative, and HER2 positive (ie, HER2); and ER negative, PR negative, and HER2 negative (ie, triple negative)...
October 10, 2011: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
label_collection
label_collection
3610
1
2
2017-02-17 01:53:03
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"